Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Profile Name||FANCA inact mut|
|Gene Variant Detail|
|Relevant Treatment Approaches|
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FANCA S1088F||Advanced Solid Tumor||sensitive||Cisplatin||Preclinical - Cell culture||Actionable||In a preclinical study, overexpression of FANCA S1088F in FANCA-null cells derived from Fanconi anemia patients resulted in increased sensitivity to Platinol (cisplatin) compared to wild-type Fanca expression in culture (PMID: 28864460).||28864460|
|FANCA S1088F||prostate cancer||predicted - sensitive||Olaparib||Preclinical - Pdx||Actionable||In a preclinical study, overexpression of FANCA S1088F in FANCA-null cells derived from Fanconi anemia patients resulted in increased sensitivity to Lynparza (olaparib) in culture, and a patient-derived xenograft (PDX) model of prostate cancer harboring germline FANCA S1088F demonstrated enhanced sensitivity to Lynparza (olaparib) treatment (PMID: 28864460).||28864460|
|FANCA inact mut||prostate cancer||predicted - sensitive||Olaparib||Case Reports/Case Series||Actionable||In a Phase II (TOPARP-B) trial, Lynparza (olaparib) treatment resulted in a composite overall response rate of 20.0% (4/20) and a RECIST objective response rate of 0% (0/17) in patients with castration-resistant prostate cancer harboring deleterious mutations in DNA damage response genes, including ARID1A, ATRX, CHEK1/2, FANCA, FANCF, FANCG, FANCI, FANCM, MSH2, NBN, RAD50, and WRN (n=1, 1, 1, 5, 5, 2, 1, 1, 2, 1, 1, 1, 7, respectively) (PMID: 31806540; NCT01682772).||31806540|
|FANCA inact mut||prostate cancer||predicted - sensitive||Rucaparib||Case Reports/Case Series||Actionable||In a Phase II trial, 1 of 4 patients with deleterious FANCA alterations demonstrated a PSA response and complete radiographic response, which were ongoing at the time of visit cutoff (PMID: 32086346; NCT02952534).||32086346|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03377556||Phase II||Talazoparib||Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer||Active, not recruiting|
|NCT03209401||Phase I||Carboplatin + Niraparib||Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies||Recruiting|
|NCT03570476||Phase II||Olaparib||Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer||Terminated|
|NCT04266912||Phase Ib/II||Avelumab + Berzosertib||Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors||Recruiting|
|NCT04019327||Phase Ib/II||Talazoparib + Temozolomide||A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer||Recruiting|
|NCT04171700||Phase II||Rucaparib||A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes (LODESTAR)||Recruiting|
|NCT03810105||Phase II||Durvalumab + Olaparib||A Study of Olaparib and Durvalumab in Prostate Cancer||Recruiting|
|NCT03840967||Phase II||Niraparib||A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma||Recruiting|
|NCT04253262||Phase Ib/II||Copanlisib + Rucaparib||A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer||Recruiting|